Inovio Pharmaceuticals, Inc.
Price Action
Technical Summary
CONSOLIDATINGInovio Pharmaceuticals, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 27), showing significant lag compared to the market leaders. Earnings growth of 100% provides fundamental context to the price action. Investors should exercise caution due to high volatility (83% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.70 | +6.68% | ABOVE |
| 50 SMA | $1.73 | +4.34% | ABOVE |
| 100 SMA | $1.96 | -7.88% | BELOW |
| 150 SMA | $2.01 | -10.14% | BELOW |
| 200 SMA | $1.97 | -8.29% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is INO in an uptrend right now?
INO has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is INO overbought or oversold?
INO's RSI (14) is 56. The stock is in neutral territory, neither overbought nor oversold.
Is INO outperforming the market?
INO has a Relative Strength (RS) Rating of 27 out of 99. INO is currently lagging the broader market.
Where is INO in its 52-week range?
INO is trading at $1.81, which is 61% of its 52-week high ($2.98) and 30% above its 52-week low ($1.30).
How volatile is INO?
INO has a Beta of 0.97 and 52-week volatility of 83%. It's less volatile than the S&P 500 - generally more stable.